About Us

Arcturus Therapeutics a global late-stage messenger RNA medicines and vaccines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases.

Our team has extensive experience in the discovery and development of mRNA medicines, as well as design and utilization of lipid-mediated drug delivery systems. This combination of in-house expertise, innovative spirit, and passion for what we do, uniquely position us to catalyze the next generation of mRNA medicines.

https://arcturusrx.com/wp-content/uploads/2023/01/Arcturus_Lobby_Large.jpg

https://arcturusrx.com/wp-content/uploads/2023/01/22ArctP750_large.jpg

https://arcturusrx.com/wp-content/uploads/2023/01/18arct1244fxF-scaled.jpg

https://arcturusrx.com/wp-content/uploads/2023/01/ArcBuilding_Final.jpg

https://arcturusrx.com/wp-content/uploads/2023/01/18arct1055fxF-scaled.jpg

https://arcturusrx.com/wp-content/uploads/2023/01/main-visual-office-exterior.jpg

https://arcturusrx.com/wp-content/uploads/2023/01/main-visual-office-interior-tag-line.jpg

https://arcturusrx.com/wp-content/uploads/2023/01/20arctlab286fxFNLLo-scaled-1.jpg

https://arcturusrx.com/wp-content/uploads/2023/01/20arctlab206fxFNLLo-scaled-1.jpg

News & Events

March 4, 2013

Arcturus Therapeutics Begins Operations in Janssen Labs

May 8, 2013

Arcturus Therapeutics Announces New Appointments to its Board of Directors and Scientific Advisory Board

September 27, 2022

Arcturus Therapeutics to Attend the Following Investor Conferences

October 26, 2022

Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022

November 1, 2022

Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines

November 8, 2022

Arcturus Therapeutics to Present at the Following Investor Conferences in November

November 9, 2022

Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress

December 12, 2022

CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics

December 13, 2022

Arcturus Appoints John Markels, Ph.D. to its Board of Directors

December 19, 2022

Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 31, 2023

Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis

March 28, 2023

Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress

April 26, 2023

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023

May 9, 2023

Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress

June 1, 2023

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency

July 24, 2023

Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023

August 7, 2023

Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress

August 14, 2023

Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government

August 17, 2023

Arcturus Therapeutics to Attend Upcoming Investor Conferences

September 5, 2023

Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19

September 19, 2023

Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants

September 26, 2023

Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis